Context:
DBT engages in a discussion with States over establishing biomanufacturing facilities for setting up an enterprise under BioE3 policy. Approved by the Union Cabinet in August 2024, BioE3 will develop the Indian scenario in the aspect of biotechnology manufacturing across states.
What is Biomanufacturing?
- Industrial production of bio based products, including
- Bio based chemicals, biopolymers, and enzymes
- Smart proteins and functional foods
- Precision biotherapeutics
- Climate resilient agriculture solutions
Key Highlights from the Consultation
- State Policies Needed
- Most States lack standalone biotechnology manufacturing policies even today.
- A strong Centre State partnership will be essential to develop the sector.
- In Example: Rajesh Gokhale, Secretary to DBT says that India requires policies that companies like Biocon should come up.
- Investment Potential
- Union Science Minister Jitendra Singh said that the biotechnology will attract enormous investment and profits.
- Those states that initiate early steps in biomanufacturing will have a competitive advantage.
- Implementation Strategy
- Establish State centric BioE3 cells.
- Develop State specific BioE3 action plans.
- Establish steering committees, working groups, and nodal officers.
- Establish Bio AI hubs, foundries, and biomanufacturing hubs.
Challenges and State Perspectives
- Several States demonstrated initiatives to promote biotechnology industries.
- However, a common complaint was the absence of financial and strategic support from the Centre.
- Scaling up biotechnology manufacturing will require substantial funding and policy guidance.
